Status:
COMPLETED
Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Neuromuscular Blockade
Arthroplasty, Replacement, Hip
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will assess the effect of reversal of neuromuscular blockade with sugammadex compared with reversal according to usual care (neostigmine or spontaneous reversal) on the incidence of post-su...
Detailed Description
Participants will be randomized to sugammadex or usual care in a 1:1 ratio.
Eligibility Criteria
Inclusion
- Must be American Society of Anesthesiologists (ASA) Class 1, 2, or 3
- Must be scheduled for a hip fracture surgery or joint (hip or knee) replacement surgery under general anesthesia including the use of rocuronium or vecuronium for neuromuscular blockade
- Must be:
- Currently receiving thromboprophylactic (anti-clotting) therapy with low molecular weight heparin (LMWH) or unfractionated heparin (UFH), or
- Planned to initiate thromboprophylactic therapy with LMWH or UFH prior to or during surgery, or
- Currently receiving ongoing thromboprophylactic therapy with a vitamin K antagonist that has been temporarily substituted with peri-operative LMWH or UFH, and/or
- Currently receiving ongoing thromboprophylactic therapy with low-dose aspirin or other antiplatelet therapy
- Platelet count above the lower limit of normal range
- Appropriate candidate for rapid reversal of neuromuscular blockade
- Sexually active females must agree to use a medically accepted method of contraception through seven days after receiving protocol-specified medication
Exclusion
- Anatomical malformations that may lead to difficult intubation
- Neuromuscular disorder that may affect neuromuscular blockade
- History of a coagulation disorder, bleeding diathesis, systemic lupus erythematosus or antiphospholipid syndrome
- History or evidence of active abnormal bleeding or blood clotting within 30 days prior to screening
- Significant hepatic dysfunction
- Severe renal insufficiency
- History or family history of malignant hyperthermia
- Hypersensitivity or hypersensitivity-like reaction to sugammadex, muscle relaxants, or other medications used during general anesthesia
- Planned intravenous administration of toremifene and/or fusidic acid within 24 hours before or within 24 hours after study medication
- Recent, severe trauma
- Body Mass Index (BMI) \> 35
- Any contraindication to administration of sugammadex or neostigmine/glycopyrrolate (or neostigmine/atropine)
- Pregnant or intends to become pregnant between randomization and the Day 30 follow-up visit
- Breast-feeding
- Previously treated with sugammadex or participated in a sugammadex clinical trial
- Has an active hip/knee infection and is scheduled for revision surgery
Key Trial Info
Start Date :
October 12 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 26 2012
Estimated Enrollment :
1198 Patients enrolled
Trial Details
Trial ID
NCT01422304
Start Date
October 12 2011
End Date
September 26 2012
Last Update
February 12 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.